



## METECH INTERNATIONAL LIMITED

(Incorporated in the Republic of Singapore)  
(Company Registration Number 199206445M)

---

### MONTHLY UPDATE FOR AUGUST 2026

---

The board of directors (the “**Board**”) of Metech International Limited (the “**Company**”) would like to provide an update on the following:

1) **The appointment of executive officers, including, but not limited to, the Chief Financial Officer (or a person with equivalent authority) of the Company (“CFO”)**

The Company has identified a candidate and has completed the necessary due diligence and internal evaluation for the appointment of the potential candidate for the role of CFO. The Company has also submitted the necessary documentation to its sponsor for their review and consideration. The Company will make the necessary announcement(s) on SGXNet should the appointment of the CFO materialise in due course.

2) **The Company’s operations**

(a) **Disposal of its 80% stake in Asian Eco Technology Pte. Ltd. (“AET”) (“Disposal”)**

The Company had, on 26 August 2026, completed the Disposal. Following the completion of the Disposal, the Company no longer holds any interest in AET and the lab-grown diamond business.

(b) **The Food Waste Business**

**Biomass Carbon Reduction System Machines**

The Company wishes to update shareholders that the biomass carbon reduction system machines, intended for the pilot trial, have arrived at the factory and have successfully completed testing and commissioning. Concurrently, the Company is actively engaging with corporations across multiple countries and industries to expand into various regional and international markets.

Concurrently, based on information provided by Colorful Paradise Agricultural Cooperation Co., Ltd. (“**CPAC**”), the Company’s joint venture partner in Taiwan, the project has received grant support as an approved initiative by the Taiwan authorities, reflecting strong market demand for such machines. To date, orders have been placed for the biomass carbon reduction system machines, underscoring the product’s viability. The Company views this as a positive development and will further strengthen its cooperation with CPAC to expand the deployment of the biomass carbon reduction system machines, including discussions on the appropriate business model and commercial arrangements going forward. In view of the grants received from the relevant authorities in Taiwan, the Company is currently in discussions with CPAC in relation to the joint fulfilment of such orders. In view of the above, the Company plans to accelerate its cooperation with CPAC in order to increase its revenue and strengthen our market presence in the region.

At the same time, the Company is working closely with the relevant Singapore government authorities. Through this cooperation, the Company expects to receive appropriate

government support, including relevant subsidies and assistance with the qualifications, approvals required for our operations and the expedition of our presence in the market. These forms of support will be important in facilitating the establishment and development of our manufacturing capabilities.

In view of these opportunities, the Company plans to establish its manufacturing facility in Singapore. Singapore will serve as our strategic base for supplying the Southeast Asian market, with the longer-term objective of expanding our products and business operations globally. Locating the factory in Singapore will allow us to position the company more effectively within the region and create a platform for international growth. Securing the appropriate facility in a timely manner will enable us to advance our cooperation with CPAC, coordinate more efficiently with the relevant Singapore authorities, take advantage of available government support, and commence our regional expansion plans without unnecessary delay.

### **Premium Protein Powder**

In relation to the non-binding memorandum of understanding with MLF Ingredients Sdn. Bhd. (“**MLF**”), the Company is in discussions with MLF on the proposed pricing of its potential high-protein animal nutrition products for the South Korea and United States markets. Concurrently, the Company is exploring collaborations with neighboring vendors to leverage their established sales networks to expand its global market reach, including in South Korea, the United States, Europe and Asia, while evaluating Malaysia as a potential manufacturing and production base for such products.

The Company possesses the technical know-how to derive high-quality food-grade protein ingredients from food valorization streams and plant-derived sources. The current formulation targets comprise approximately 40% protein derived from food industry by-products and valorization sources, including soy waste, brewer’s extract residues and dairy waste streams, with the remaining 60% derived from plant-based ingredients. To validate the protein content of the product, the Company had commissioned an independent third-party laboratory test.

The Company is exploring commercialization opportunities for applications including premium animal feed, baby animal nutrition, senior meal replacement products and infant nutrition formulations, subject to applicable regulatory approvals and market requirements. Management believes the high-quality protein formulations may contribute to improved nutritional outcomes, enhanced digestibility, reduced mortality rates in young animal applications and overall improved health performance.

Notwithstanding the foregoing, in light of the business developments, the Company plans to manufacture and/or assemble key components of its machines in Singapore, therefore requiring a suitable factory space.

In connection with the aforementioned the Company has reached an in-principle understanding with the vendor of the factory in relation to a potential investment, with a view to reducing operational costs.

In this regard, the Company will make the relevant announcements in accordance with the Catalist Rules as and when there are any material developments, including the entry into definitive agreements with the vendor (if any).

### **(c) The Health Supplements Business**

To meet increasing demand, the Company is working with its suppliers to scale production capabilities in China, through strategic supplier partnerships and enhancing its sales initiatives. Additionally, the Company is evaluating the introduction of innovative

supplements to the market, such as Soy Oligopeptide, Okra Polysaccharide, Dibipro, Oyster Peptide, and Okra drinks.

In view of the above development, the Company plans to increase its purchases from the suppliers in order to maximize its revenue in the coming months.

3) **The placement of 100,000,000 new ordinary shares (“Placement Shares”) in the capital of the Company (the “Placement”)**

As announced by the Company on 30 July 2026, the Company has partially completed the Placement with Mr. Ma Ong Kee and Raffles Capital Limited, raising net proceeds of approximately S\$2,856,000 (the “**Net Proceeds**”).

The Board would like to provide an update on the utilisation of the Net Proceeds from the Placement. The Company had, in the Placement announcement dated 26 June 2026, disclosed that all of the Net Proceeds would be utilised for general working capital purposes.

Change in use of proceeds

The Company had on 15 July 2026 reallocated the Net Proceeds to include the repayment of loans amounting to an aggregate amount of S\$1,000,000 (the “**Reallocation**”). The changes in and the details on the use of the Net Proceeds as at the date of this announcement are as follows:

|                                  | <b>Allocation<br/>(S\$'000)</b> | <b>Allocation after<br/>the<br/>Reallocation<br/>(S\$'000)</b> | <b>Amount<br/>utilised<br/>(S\$'000)</b> | <b>Balance<br/>(S\$'000)</b> |
|----------------------------------|---------------------------------|----------------------------------------------------------------|------------------------------------------|------------------------------|
| General working capital purposes | 2,856                           | 1,856                                                          | (746)                                    | 1,110                        |
| Repayment of loans               | -                               | 1,000                                                          | (1,000)                                  | -                            |
| <b>Total</b>                     | 2,856                           | 2,856                                                          | (1,746)                                  | 1,110                        |

General working capital purposes refer to (a) professional fees of S\$277,553, (b) employee salaries and benefits expenses of S\$122,752, (c) Directors' fees of S\$65,722, (d) suppliers' payment of S\$100,000, (e) office related expenses of S\$76,320 and (f) administrative and miscellaneous expenses of S\$103,863.

By Order of the Board of Directors of  
**Metech International Limited**

Pang Wei Hao  
Executive Director and Chief Executive Officer

31 August 2026

---

*This announcement has been reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.*